ストックスクリーナーアプリを入手
33.02
3.51%
1.12
アフターアワーズ：
33.02
Crinetics Pharmaceuticals Inc (CRNX) 最新ニュース
Crinetics stock maintains Buy rating at Jones Trading on positive ENDO’25 data - Investing.com Canada
Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs - Insider Monkey
what makes crinetics pharmaceuticals inc. stock price move sharplySafer Investing With Bigger Upside - Newser
What makes Crinetics Pharmaceuticals Inc. stock price move sharplyFree Wealth-Building Investment Strategies - Newser
Why Crinetics Pharmaceuticals Inc. stock attracts strong analyst attentionFree Investment Community - Newser
How Crinetics Pharmaceuticals Inc. stock performs during market volatilityChart Based Entries - Newser
JMP reiterates Market Outperform rating on Crinetics stock as paltusotine shows strong data - Investing.com Nigeria
Teacher Retirement System of Texas Sells 1,561 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly - Benzinga
Crinetics reveals new data from acromegaly therapy programme - Yahoo Finance
New data for oral acromegaly drug ahead of approval decision - The Pharma Letter
Acromegaly's Next Frontier: Crinetics' PALSONIFY Aims to Overhaul Treatment Standards - AInvest
Crinetics Pharmaceuticals New Data Show Durable Control of Palsonify in Acromegaly - MarketScreener
CRNX to Highlight PALSONIFY Data at ENDO 2025 | CRNX Stock News - GuruFocus
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 - The Manila Times
Crinetics Pharmaceuticals Presents New Long-Term Data on PALSONIFY for Acromegaly at ENDO 2025 - Quiver Quantitative
Breakthrough: Crinetics' Once-Daily Oral PALSONIFY Matches Injectable Treatments in 96-Week Acromegaly Study - Stock Titan
Crinetics to Present New Long-Term Data Demonstrating Durable Co - GuruFocus
Amalgamated Bank Boosts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
The Goldman Sachs Group Initiates Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financia - GuruFocus
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 - Yahoo Finance
Goldman Sachs initiates coverage on Crinetics stock with Neutral rating By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants - GuruFocus
Crinetics Expands Team with 46 New Hires, Grants $3.2M+ in Equity Compensation - Stock Titan
Goldman Sachs Initiates Crinetics Pharmaceuticals at Neutral With $36 Price Target - MarketScreener
Goldman Sachs Begins Coverage of Crinetics (CRNX) with Neutral O - GuruFocus
Should You Hold Crinetics Pharmaceuticals (CRNX)? - Insider Monkey
KBC Group NV Grows Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Hyperparathyroidism Pipeline 2025: Groundbreaking Clinical - openPR.com
Crinetics Pharmaceuticals’ SWOT analysis: stock poised for growth in endocrine treatments - Investing.com Australia
Crinetics Pharmaceuticals’ SWOT analysis: stock poised for growth in endocrine treatments By Investing.com - Investing.com South Africa
Contrasting Crinetics Pharmaceuticals (NASDAQ:CRNX) & Vaxart (NASDAQ:VXRT) - Defense World
Crinetics stock rating reiterated at Market Outperform by JMP ahead of key data - Investing.com Canada
Crinetics to Showcase the Next Generation of Endocrinology Innov - GuruFocus
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline - TradingView
New Oral Treatment Breakthrough: Crinetics Reveals Long-Term Success Data for Acromegaly Drug at ENDO 2025 - Stock Titan
Crinetics Pharmaceuticals’ (CRNX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Crinetics Pharmaceuticals (CRNX) Stock Update: Analyst Maintains - GuruFocus
Crinetics Pharmaceuticals (CRNX) Stock Update: Analyst Maintains 'Buy' Rating | CRNX Stock News - GuruFocus
GAMMA Investing LLC Has $227,000 Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Trading (CRNX) With Integrated Risk Controls - news.stocktradersdaily.com
Crinetics to Unveil Critical Pipeline Updates: New Data on NETs, Graves Disease, and Kidney Disease Programs - Stock Titan
Crinetics Pharmaceuticals: Highly Priced Biotech Awaits PDUFA On Acromegaly Drug - Seeking Alpha
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 - The Manila Times
Rhumbline Advisers Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Research Analysts Offer Predictions for CRNX FY2026 Earnings - Defense World
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants - GuruFocus
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
(CRNX) Trading Report - news.stocktradersdaily.com
Two Sigma Advisers LP Sells 14,300 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Jane Street Group LLC Sells 122,188 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Thinking Of Buying Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Stock? Here Is What You Should Know - Stocksregister
H.C. Wainwright maintains Crinetics stock Buy rating, $81 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains Crinetics stock Buy rating, $81 target - Investing.com India
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):